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Clinical Experience With Horse Antihuman ALG 
By Thomas E. Starzl, Carl G. Groth, N. Kashiwagi, Charles W. Putnam, 
Jacques l. Corman, Charles G. Halgrimson, and Israel Penn 
THERE will be little point in dwelling on 
our clinical experience with ALG, 
though this has been extensive. The reason 
is that we have not carried out a con-
temporaneous control study omitting ALG. 
We do not have, as a consequence, proof 
that our results were improved by the 
clinical introduction of ALG. Nevertheless, 
there is evidence supporting this point of 
view which we will briefly describe. 
Related Transplantations 
Our first renal homotransplantations 
were carried out in 1962. If related donors 
could be found, substantial benefits for 
the majority of recipients were obtained 
from the very beginning of our experience. 
In Fig. 1 is shown graphically the fate 
of 131 consecutive patients who were given 
kidneys by siblings, parents, or more 
distantly related donors such as aunts, 
uncles, or cousins, between 1962 and 
Spring 1968. The follow-up in Series 1 is 
now 8-91/2 yr, in Series 2 from 6-71/2 yr, 
and in Series 3 from 4-6 yr. 
The 71 patients of Series 1 and 2 were 
treated with azathioprine and prednisone. 
Tissue-typing techniques were not used in 
Series 1 since they were not yet available. 
In Series 2, an effort was made by Dr. 
Paul Terasaki of Los Angeles to select 
the best donor among those available in 
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any given case. This effort of donor dis-
crimination was not beneficial (Fig. 1) and, 
in fact, the eventual survival was somewhat 
inferior to that in Series 1. 
The 60 patients of Series 3 were ad-
ministered horse antilymphocyte globulin 
(ALG) in addition to azathioprine and 
prednisone. With minimum follow-ups of 
at least 4 yr, the survival of both patients 
and grafts appears to have been increased 
(Fig. 1). Even today, after 4-6 yr, 75% 
of these ALG-treated patients are still alive 
and all but three of the survivors (42 of 
45) have acceptable function of their ori-
ginal homografts. 
Generally, the ALG-treated patients had 
globulin therapy for about 4 mo post-
transplantation, with intramuscular injec-
tions of 3-6 mg/kg. The ALG was started 
several days before operation and given 
daily for 2 wk, every other day for 2 wk, 
twice a week for 2 mo and once a week 
for a final month. Because they were the 
only available source of human lymphoid 
tissue in large quantities, human spleens 
were used in this era to raise the ALG, 
with careful attention being paid to separat-
ing the leukocytes from stroma, platelets, 
and red cells before their inoculation into 
horses. After absorption and purification, 
the eventual product usually had lympho-
cytotoxic and leukoagglutinin titers of 1: 
4000 or preferably greater. Anti-GBM acti-
vity was not demonstrable or very minimal 
in the Dixon rat model. 
Nonrelated Homografts 
As with the consanguineous cases, the 
introduction of ALG as part of a triple 
drug treatment program was associated 
with an improvement in results. This is 
demonstrated in Fig. 2, in which Series 1 
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Fig. 1. Life survival curves of three groups of recipients of consanguineous kidneys. The 
patients in Series 1 were treated with the double drug program of azathioprine and 
prednisone from 1962 to March 1964 and, consequently, have potential follow-ups of 8 to 
91/2 yr. The patients of Series 2 were treated from October 1964 to April 1966 and, con-
sequently, have potential follow-ups of 6-71/2 yr. They received the same drug therapy as 
in Series 1 and, in addition, an attempt was made at donor selection by HL-A matching. 
The recipients of Series 3 were treated with the triple drug program of azathioprine, 
prednisone, and ALG between June 1966 and April 1968; they have potential follow-ups 
of 4-6 yr. In all three series, the denominator indicates the surviving patients whereas the 
numerator tells the number of originally transplanted kidneys that are still functioning in 
those survivors. 
and 2 conform to the same intervals de-
fined in the preceding section, and in which 
Series 3 is also comparable except that 
cases were included through April 1969. 
In the 1962-66 era, the patient survival 
rate at 1 yr was between 33% and 52%. 
In Series 3, this1-yr figure rose to 82% (14 
of 17 patients). After 1 yr, in all three 
series, including the final ALG group, the 
ultimate survival has drifted off far more 
rapidly than with the use of related homo-
grafts. 
Is There an Indispensable Drug? 
Subsequent to the completion of Series 
3, and continuing until February 1971, more 
than 160 additional patients were given 
either related or cadaveric renal homografts 
under immunosuppressive therapy with 
azathioprine, prednisone, and ALG. In a 
general way, the results were confirmatory 
of those in Series 3, although the survival 
was not quite so high, primarily because 
the medical criteria for acceptance to the 
program were so drastically relaxed. Final-
ly, for more than 1 yr, cyclophosphamide 
has been used in place of azathioprine in 
a triple drug program that includes steroids 
and ALG. Here, too, the results have been 
good, both in related and nonrelated cases 
HORSE ANTIHUMAN ANTILYMPHOCYTE GLOBULIN 493 
1·0 
.9 
NON-RELATED HOMOGRAFTS 
SERI ES I -18 VOLUNTEERS 
SERIES]I (TYPED) -17 VOLUNTEERS 
AND 6 CADAVERS 
SERIESm (ALG)-17 CADAVERS ~ ~ ;; .8\" 
- f~ ~ .7 I'" 
Fig. 2. The results after trans-
plantation of non-related kidneys. 
The conditions of treatment and 
the meaning of the figures in the 
parentheses are identical to 
those in Fig. 1. Note that the 
results with non related kidneys 
have been inferior to those with 
related grafts at all levels of our 
experience. The follow-ups are 
also the same as in Fig. 1 except 
in Series 3, in which the poten-
tial follow-ups are 3-6 yr. 
CJ) .6 I -\ 
1 ~y t5 .5 I '-; ____ , 
f- .4 l, " ~ 3 L\ D----~_K 
LL . -1 '----, IT 
.2 
as has been described in another paper of 
this symposium. 
In reviewing our experience of the last 
decade, the point can be made that the 
one absolutely indispensable agent that 
has made renal transplantation practical 
is prednisone. More than occasional suc-
cesses are possible with the omission of 
either one or two of the three other major 
agents we have mentioned, namely aza-
thioprine, cyclophosphamide, or ALG. 
However, without adrenal corticosteroids, 
we believe that the management and re-
versal of rejection would be so seldom 
achievable that the clinical discipline of 
renal transplantation would vanish. 
It is in this context that ALG must be 
evaluated. We have always considered ALG 
to be an adjuvant immunosuppressant, and 
one which is of the greatest value for 
short-term use during the often difficult 
early postoperative period when the issue 
of graft acceptance or failure is most com-
monly decided. When used in this way, 
rather than as a panacea, we have been 
convinced that ALG is an important part 
of our therapeutic armamentarium and one 
that has not only improved survival but 
also the quality of convalescence. 
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Problems in the Future of ALC 
There is probably not an appropriately 
informed responsible scientist in the world 
who does not concede that ALG is a potent 
immunosuppressive agent in humans. But 
that is not the question that perplexes 
clinicians interested in renal transplanta-
tion. Rather, the issue is whether or not 
ALG fills some unique role that cannot 
be equally well met by the clever manipula-
tion of other agents such as steroids, aza-
thioprine, and cyclophosphamide. For this 
purpose more controlled trials such as 
those of Sheil will be welcomed. 
One reason why the true clinical value 
of ALG must be settled is the tremendous 
investment of personnel and material re-
sources that have been required to make 
ALG available for human use. At a recent 
conference in Bad Soden, Germany, ex-
amples were cited in which the cost of 
ALG accounted for half the financial in-
vestment to treat a renal recipient. In 
addition, the amount of talent that is 
required to ensure a supply is amazing. 
These efforts and expenses will be worth-
while only if tangible and substantial bene-
fits are demonstrable. This is particularly 
true since in addition to the nuisance of 
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procuring it there are potential dangers 
with the administration of ALG. Anaphyl-
axis, which has led to several deaths, is 
the most terrifying side effect, but there 
are others, including injection site pain, 
thrombocytopenia, and injury to the homo-
graft itself, to mention only a few. 
No matter how useful heterologous ALG 
proves to be, there will remain very major 
problems of standardization. There are 
four exceptionally sensitive points that 
must be clarified: (1) the best animal in 
which to raise ALS; (2) the most effective 
immunization schedule to be used; (3) the 
correct antigen; and (4) the in vitro tech-
niques for evaluating the effectiveness of 
the product. All of these matters were 
considered at the Bad Soden, Germany, 
ALG conference in April 1972, as well as 
at an earlier meeting at San Diego, Cali-
fornia, held in December 1971. 
The consensus from these discussions 
was that the choice of animal is probably 
not a crucial factor. The schedule of im-
munization is probably also not critical 
except that if the course is a short and 
standard one according to the Monaco-
Medawar principle the ultimate product is 
apt to be relatively the same from animal 
to animal. In horses, this has been shown 
in our laboratories in five animals sub-
mitted to three-pulse immunization with 
large numbers of lymphoblasts (Fig. 3). 
The resulting high titer ALG prolonged 
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survival of rhesus skin homo grafts to 24 
days (controls <12). 
The third question about the best anti-
gen source is still open for discussion. The 
thymocyte has a number of advocates, but 
from the viewpoint of convenience and 
purity, a contender, as we have heard from 
Condie, is the cultured lymphoblast which, 
so far as we know, represents a pure B-
cell population. 
Concerning the fourth point, there has 
been a gradual acceptance of at least four 
in vitro tests. Even a year ago there were 
flat denials that the leukoagglutinin and 
lymphocytotoxicity tests had any correla-
tion with immunosuppressive effect, al-
thou)!h it was commonly conceded that 
correlations were good with the rosette 
inhibition test of J. F. Bach. Yet at the 
German conference, data were presented 
with rabbit ALG showing that cyto-
toxicity titers and potency in the monkey 
skin test system had an almost perfect 
correlation. In other studies with the horse 
it was demonstrated from more than one 
laboratory that four current titration meth-
ods yielded about the same answer (cyto-
toxicity, leukoagglutination, rosette inhibi-
tion, and micro complement fixation) and 
that the heights of these titers were a 
relatively direct measure of the immuno-
suppressive quality as cross checked in the 
surrogate monkey model. It was pointed 
out that methodologic artifacts in measure-
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Fig. 3. Anti-white-cell titers in 
five horses undergoing three-
pulse immunization with human 
cultured Iymphoblasts. 
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ment of anti-white-cell titers may have 
accounted for discrepancies in the past. 
It may be superfluous to engage in much 
debate about the dose and administration 
schedules of such a poorly standardized 
agent as ALG. Nevertheless, it is important 
to attempt this by those who are or are 
planning to give ALG now. In our center 
we have tried to use ALG with a minimum 
leukoagglutination and cytotoxicity titer of 
1 :8000, in volumes for adults of 4-5 ml 
per injection intramuscularly. Since the 
protein content is 5 g% the dose per in-
jection is usually 4-5 mg/kg. It should be 
noted that this kind of dose in the Sim-
mons dose-response curve, worked out in 
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patients with multiple sclerosis, caused an 
easily detectable prolongation of human 
skin graft survival. If these doses are 
further reduced either by using poor titer 
material or by decreasing the volume of 
injectate one may easily enter into a homeo-
pathic range. If alternating case studies of 
renal transplantation are carried out, it is 
to be hoped that ALG will not be dis-
credited by making this mistake of under-
dosage. Because of the danger of sensitiza-
tion to the foreign protein, ALG therapy 
will probably have to continue to be re-
stricted to the first few postoperative weeks 
or months. 
